About IPST
Our team has always been a hybrid; a pairing of academic open-mindedness and flexibility, with the dynamics of the fast-paced private sector.
Our story
Learning about each of you made us who we are today. A cornerstone of IPST’s business model is the belief that it is essential to create long-term partnerships with our clients.
- Founded in 1999 by brothers Gilles and Pierre Sirois.
- More than 90% of our clients are return clients. We attribute this exceptional loyalty to our collaborative model.
- IPS Therapeutique has worked on thousands of compounds. Many have now become commercial drugs. Examples? A well-known treatment for erectile dysfunction, anti-arrhythmics, anti-hypertensives, asthma treatments, etc.
- Our clients range from small start-ups to mature pharmaceutical companies from around the world.
An open mind is the essence of success
IPST’s trademark collaborative model came as a consequence of the intellectual interaction of scientists working together as a purpose-driven team to create successful studies and long-term collaborations. As our relationships with clients flourished, so did requests for new models and endpoints. Those validated models have merged into families of services: cardiovascular, respiratory, bleeding, and inflammatory.
Just like wine in a cask, “what I love most” has changed over the years. From running the experiments myself, to designing them to be run by others, the initial steps have always been my favourite, I think. It’s that moment when a sponsor explains the challenge he/she’s facing, and together, we brainstorm to assemble a solution. Eventually, a ground-breaking idea -a parameter, a test, anything- comes to mind, which crystallizes the solution. At that point, we both know that this idea changes everything: it collapses obstacles and opens the path forward. That moment has remained one of my greatest motivators, throughout the years. – Dan Salvail, IPST